Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.

ABSTRACT:

Background

A patient suffering from metastatic colorectal cancer, treatment-related toxicity and resistance to standard chemotherapy and radiation was assessed as part of a personalized oncogenomics initiative to derive potential alternative therapeutic strategies.

Patients and methods

Whole-genome and transcriptome sequencing was used to interrogate a metastatic tumor refractory to standard treatments of a patient with mismatch repair-deficient metastatic colorectal cancer.

Results

Integrative genomic analysis indicated overexpression of the AP-1 transcriptional complex suggesting experimental therapeutic rationales, including blockade of the renin-angiotensin system. This led to the repurposing of the angiotensin II receptor antagonist, irbesartan, as an anticancer

SUBMITTER: Jones MR 

PROVIDER: S-EPMC4843189 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature